Difference between revisions of "Cook N, et al. Br. J. Cancer (2018) cited as Ref 580 in DOI: 10.1038/s41392-020-0110-5 (Q9843)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created a new Item: #quickstatements; #temporary_batch_1589975872009)
 
(‎Created claim: Page(s) (P105): 793-801, #quickstatements; #temporary_batch_1590074839150)
 
(8 intermediate revisions by the same user not shown)
Property / First Author string
 +
Cook N
Property / First Author string: Cook N / rank
 +
Normal rank
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1038/bjc.2017.495 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 29438372 / rank
 +
Normal rank
Property / Publication Date
 +
2018
Timestamp+2018-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2018 / rank
 +
Normal rank
Property / Published In Name String
 +
Br. J. Cancer
Property / Published In Name String: Br. J. Cancer / rank
 +
Normal rank
Property / Volume
 +
118
Property / Volume: 118 / rank
 +
Normal rank
Property / title
 +
A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (English)
Property / title: A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
793-801
Property / Page(s): 793-801 / rank
 +
Normal rank
links / sliswiki / namelinks / sliswiki / name
 +

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Cook N, et al. Br. J. Cancer (2018) cited as Ref 580 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Cook N
    0 references
    0 references
    2018
    0 references
    Br. J. Cancer
    0 references
    118
    0 references
    A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (English)
    0 references
    793-801
    0 references